DACARBAZINE
Metastatic malignant melanoma. Hodgkin's disease. Soft tissue sarcomas.
Malignant melanoma: 2-4.5 mg/kg/day for 10 days. Hodgkin’s disease: 150 mg/sq m/day for 5 days. Treatment may be repeated after 4 weeks.
Pregnancy, lactation, marrow suppression, hypersensitivity.
Hematological monitoring periodically warranted. Restrict food intake 4-6 hours prior to therapy, Caution in handling-irritant to skin & tissues. Renal & hepatic impairment. Paediatrics: Reduced dose necessary. Pregnancy: Contraindicated. Lactation: Contraindicated. Elderly: Use with caution.
Bone marrow suppression, hepaitc impairment, flu-like syndrome, facial flushing, rash, CNS disturbances, blurred vision, paresthesia, anorexia, nausea, vomiting, alopecia, Budd-chiari syndrome.
Dacarbazine may impair immunological response to live vaccine with development of a generalised vaccinia. It forms a precipitate with hydrocortisone succinate.
